John D Greiner

US Patent:

8484309, Jul 9, 2013

Filed:

Feb 20, 2007

Appl. No.:

11/676525

Inventors:

Paul Bong - Cary NC, US
Jeffrey M. Eichen - Apex NC, US
Jeffrey L. Fairbrother - Raleigh NC, US
John W. Greiner - Raleigh NC, US
Jerrold M. Heyman - Raleigh NC, US

Assignee:

International Business Machines Corporation - Armonk NY

International Classification:

G06F 15/16
G06F 7/04
H04L 29/06

US Classification:

709217, 709218, 709219, 713164, 713165, 713166, 713167, 726 27, 726 28, 726 29, 726 30

Abstract:

A method, system and computer program product for controlling an access to a data resource are disclosed. According to an embodiment, a method for controlling an access to a data resource comprises: communicating a request for the access to the data resource from a requester to an owner of the data resource for validation, the communicating being implemented by a network server; and generating information required by an access implementation server to implement a validated access and updating a data storage device with the generated information.

US Patent:

20040091995, May 13, 2004

Filed:

Jul 16, 2003

Appl. No.:

10/297168

Inventors:

Jeffrey Schlom - Potomac MD, US
John Greiner - Ijamsville MD, US
Erik Kass - Chevy Chase MD, US
Dennis Panicali - Acton MA, US

International Classification:

A61K039/275
A61K039/285
C12N007/00
A61K048/00

US Classification:

435/235100, 424/232100, 424/093200

Abstract:

Replication-defective recombinant poxvirus encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) are disclosed for use in enriching an immunization site with antigen-presenting cells (APC), for enhancing an immunological response to antigen or immunological epitopes by functioning as a biological adjuvant, for prevention or treatment of neutropenia, and for the treatment of myeloidysplastic syndromes. Compositions comprising a replication-defective recombinant virus encoding GM-CSF alone or in combination with a recombinant virus encoding an antigen and optionally encoding an immunostimulatory molecule are disclosed for enhancing antigen-specific immunological responses, in particular enhancing tumor antigen responses for anti-tumor therapy. Methods for enriching an immunization site with APC and for enhancing immunological responses to an antigen or immunological epitope using replication-defective recombinant poxvirus encoding GM-CSF are disclosed. The superiority of the use of a replication-defective recombinant avian poxvirus encoding GM-CSF over the use of recombinant GM-CSF is described.

US Patent:

20100150960, Jun 17, 2010

Filed:

Sep 21, 2007

Appl. No.:

12/442483

Inventors:

Jeffrey Schlom - Potomac MD, US
David A. Zaharoff - Fayetteville AR, US
John W. Greiner - Ijamsville MD, US

Assignee:

The United States of America, as represented by the Secretary,Department of Health and Human Servi - BETHESDA MD

International Classification:

A61K 39/21
A61K 39/00
A61P 31/12
A61K 39/145
A61K 39/29
A61K 39/015
A61K 38/19
A61P 37/04
A61P 31/16
A61P 31/18
A61P 35/00

US Classification:

4242081, 4241841, 4242091, 4242251, 4242721, 514 12, 977773

Abstract:

The present invention features methods and compositions related to chitosan antigen depots, and chitosan cytokine depots, and the use of depot compositions in treating and preventing diseases.